On August 16, 2019, FDA approved transcatheter aortic valve replacement (TAVR) in severe aortic stenosis patients at low-risk for surgery. This was a highly-anticipated move following the compelling results of low-risk TAVR trials presented earlier this year at the American College of Cardiology Scientific Session. Unlike previous indication expansions, FDA approved both the Medtronic and Edwards valves at once.
Create your free account to access 2 resources each month, including the latest research and webinars.
You have 2 free members-only resources remaining this month remaining this month.
1 free members-only resources remaining this month
1 free members-only resources remaining this month
Never miss out on the latest innovative health care content tailored to you.